Yan‐Shen Shan - Concepedia

Author

Yan‐Shen Shan

National Cheng Kung University Hospital ORCID

Also Known As

Hao-Chen Wang, Shan Y., Shan, Yan-Shen, Y S Shan, Y Shan, Y. S. Shan, Y. Shan, Y.-S. Shan, Y.K. Shan, Y.S. Shan

371

Publications

7.4K

Citations

H-Index

124

Concepts

All Affiliations

National Cheng Kung University Hospital National Cheng Kung University National Health Research Institutes Kaohsiung Medical University Kaohsiung Medical University Chung-Ho Memorial Hospital

About

Yan‐Shen Shan is an author at National Cheng Kung University Hospital specializing in medicine, cancer research, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	51	2.9K
2	Health Sciences	4	4	81
3	Engineering	3	3	117
4	Social Sciences	2	2	60
5	Natural Sciences	1	1	70

Yan‐Shen Shan

144

Publications

6.3K

Citations

H-Index

Page 1

	Year	Citations
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky, The Lancet NanomedicineOncologyPancreatic CancerMedicineFolinic Acid	2015	1.2K
Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine Ming-Chen Yang, Hao‐Chen Wang, Ya-Chin Hou, Molecular Cancer	2015	184
Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells Tze‐Sian Chan, Chung‐Chi Hsu, Vincent C. Pai, The Journal of Experimental Medicine	2016	164
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer J.S. Chen, Chih‐Hung Hsu, Nai‐Jung Chiang, Annals of Oncology Gastrointestinal OncologyMedicineBiliary CancerPathologyMolecular Oncology	2015	157
Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Journal of Clinical Oncology	2022	120
Elevated Serum Interleukin-8 Level Correlates with Cancer-Related Cachexia and Sarcopenia: An Indicator for Pancreatic Cancer Outcomes Ya‐Chin Hou, Chih‐Jung Wang, Ying‐Jui Chao, Journal of Clinical Medicine	2018	104
Predictors for Patterns of Failure after Pancreaticoduodenectomy in Ampullary Cancer Hui‐Ping Hsu, Ta-Ming Yang, Yu‐Hsiang Hsieh, Annals of Surgical Oncology Surgical OncologyPancreatic CancerGastrointestinal OncologyMedicineAmpullary Cancer	2006	101
Low CD8+ T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44+/CD133+ Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer Ya-Chin Hou, Ying‐Jui Chao, Min-Hua Hsieh, Cancers ImmunologyImmune RegulationImmunoeditingCd4 T Cell ResponsesImmunotherapeutics	2019	101
Coexpression of CD44‐positive/CD133‐positive cancer stem cells and CD204‐positive tumor‐associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma Ya‐Chin Hou, Ying‐Jui Chao, Hui‐Ling Tung, Cancer	2014	100
A Gene Expression Signature of Epithelial Tubulogenesis and a Role for ASPM in Pancreatic Tumor Progression Wei–Yu Wang, Chung‐Chi Hsu, Ting–Yun Wang, Gastroenterology Pancreatic Tumor ProgressionGene Expression SignatureDevelopmental BiologySignaling PathwayPancreatic Cancer	2013	98

Page 1